(Reuters) - By Ransdell Pierson
NEW YORK, May 31 - Dendreon Corp. on Thursday said the U.S. Food and Drug Administration has informed it that positive interim or final survival data from an ongoing trial of its Provenge cancer vaccine would satisfy the agency's earlier request for more data, lifting shares 42 percent.
Read more at Reuters.com Government Filings News
NEW YORK, May 31 - Dendreon Corp. on Thursday said the U.S. Food and Drug Administration has informed it that positive interim or final survival data from an ongoing trial of its Provenge cancer vaccine would satisfy the agency's earlier request for more data, lifting shares 42 percent.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment